Literature DB >> 19637229

Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.

Silvia K Schmidt1, Anika Müller, Kathrin Heseler, Claudia Woite, Katrin Spekker, Colin R MacKenzie, Walter Däubener.   

Abstract

In mammals, the regulation of local tryptophan concentrations by the IFN-gamma-i inducible enzyme IDO is a prominent antimicrobial and immunoregulatory effector mechanism. Here, we show for the first time that another tryptophan-degrading enzyme, the liver-specific tryptophan 2,3-dioxygenase (TDO), is also capable of mediating antimicrobial and immunoregulatory effects. Using a tetracycline inducible eukaryotic system, we were able to express recombinant TDO protein, which exhibits functional properties of native TDO. We found that HeLa cells expressing recombinant TDO were capable of inhibiting the growth of bacteria (Staphylococcus aureus), parasites (Toxoplasma gondii) and viruses (herpes simplex virus). These TDO-mediated antimicrobial effects could be blocked by the addition of tryptophan. In addition, we observed that, similar to IDO-positive cells, TDO-positive cells were capable of inhibiting anti CD3-driven T-cell proliferation and IFN-gamma production. Furthermore, TDO-positive cells also restricted alloantigen-induced T-cell activation. Here, we describe for the first time that TDO mediates antimicrobial and immunoregulatory effects and suggest that TDO-dependent inhibition of T-cell growth might be involved in the immunotolerance observed in vivo during allogeneic liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19637229     DOI: 10.1002/eji.200939535

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  42 in total

1.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Authors:  Luc Pilotte; Pierre Larrieu; Vincent Stroobant; Didier Colau; Eduard Dolusic; Raphaël Frédérick; Etienne De Plaen; Catherine Uyttenhove; Johan Wouters; Bernard Masereel; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

3.  Cell death of gamma interferon-stimulated human fibroblasts upon Toxoplasma gondii infection induces early parasite egress and limits parasite replication.

Authors:  Wendy Niedelman; Joris K Sprokholt; Barbara Clough; Eva-Maria Frickel; Jeroen P J Saeij
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

Review 4.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

Authors:  Ikwunga Wonodi; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-02-10       Impact factor: 9.306

5.  Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells.

Authors:  Richeng Mao; Jiming Zhang; Dong Jiang; Dawei Cai; Jessica M Levy; Andrea Cuconati; Timothy M Block; Ju-Tao Guo; Haitao Guo
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

6.  Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.

Authors:  Quentin Lepiller; Eric Soulier; Qisheng Li; Mélanie Lambotin; Jochen Barths; Dietmar Fuchs; Françoise Stoll-Keller; T Jake Liang; Heidi Barth
Journal:  J Innate Immun       Date:  2015-03-19       Impact factor: 7.349

7.  Guanylate-binding protein 1 (GBP1) contributes to the immunity of human mesenchymal stromal cells against Toxoplasma gondii.

Authors:  Aiping Qin; De-Hua Lai; Qifa Liu; Weijun Huang; Ya-Ping Wu; Xiaoyong Chen; Sunxing Yan; Huimin Xia; Geoff Hide; Zhao-Rong Lun; Francisco J Ayala; Andy Peng Xiang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-25       Impact factor: 11.205

8.  Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.

Authors:  F M Notarangelo; E H Wilson; K J Horning; M A R Thomas; T H Harris; Q Fang; C A Hunter; R Schwarcz
Journal:  Schizophr Res       Date:  2013-12-15       Impact factor: 4.939

Review 9.  Metabolic control of tumour progression and antitumour immunity.

Authors:  Lei Huang; Andrew L Mellor
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

10.  Oxidative stress and tryptophan degradation pattern of acute Toxoplasma gondii infection in mice.

Authors:  Ayse Basak Engin; Funda Dogruman-Al; Ugur Ercin; Bekir Celebi; Cahit Babur; Neslihan Bukan
Journal:  Parasitol Res       Date:  2012-07-12       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.